Europe Drug Discovery Market (2020 to 2030) – Trend Forecast and Growth Opportunities – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Europe Drug Discovery Market 2020-2030 by Drug Type, Service, Process, Technology, Therapeutic Area, End User, and Country: Trend Forecast and Growth Opportunity” report has been added to ResearchAndMarkets.com’s offering.

Europe drug discovery market was valued at $14.8 billion in 2020 and will grow by 8.3% annually over 2020-2030 owing the rising demand for specialty medicines, the surge in lifestyle-oriented diseases and the advancements in technology, the growing elderly population and the rising healthcare expenses, rising expenditure on R&D, and expiration of patents.

Key Players:

• Abbott Laboratories Inc.
• Agilent Technologies Inc.
• Astrazeneca plc
• Bayer AG
• Charles River Laboratories International Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline PLC
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.
• Shimadzu Corp
• Thermo Fisher Scientific Inc.

The report is based on a comprehensive research of the entire Europe drug discovery market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain.

The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19).

In-depth qualitative analyses include identification and investigation of the following aspects:

• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Five Forces

The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe drug discovery market in every aspect of the classification from perspectives of Drug Type, Service, Process, Technology, Therapeutic Area, End User, and Country.

Based on Drug Type, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.

• Small Molecule Drugs
• Biologic Drugs

Based on Service, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.

• Medicinal Chemical Services
• Biological Services
• Drug Metabolism and Pharmacokinetics (DMPK) Services
• Other Pharmaceutical Services

Based on Process, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.

• Target Selection
• Target Validation
• Hit-To-Lead Identification
• Lead Optimization
• Candidate Validation

Based on Technology, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.

• High Throughput Screening
• Combinatorial Chemistry
• Pharmacogenomics and Pharmacogenetics
• Nanotechnology
• Bioanalytical Instruments
• Biochips
• Bioinformatics
• Other Technologies

Based on Therapeutic Area, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.

• Oncology
• Neurology
• Infectious and Immune System Diseases
• Digestive System Diseases
• Cardiovascular Diseases
• Diabetes
• Respiratory Disease
• Other Therapeutic Areas

Based on End User, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2019-2030 included in each section.

• Pharmaceutical Companies
• Contract Research Organizations (CROs)
• Research Institutes
• Other End Users

Geographically, the following national/local markets are fully investigated:

• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe (further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)

For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2019-2030. The breakdown of key national markets by Drug Type, Service, and Therapeutic Area over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

For more information about this report visit https://www.researchandmarkets.com/r/3sbur7

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900